| Literature DB >> 27525008 |
Huibin Huang1, Lijun Chen2, Bo Liang1, Huiyao Cai1, Qingyan Cai1, Yaxiong Shi1.
Abstract
Objective. It has been testified that iodine regulates thyroid function by controlling thyroid-restricted genes expression and is closely related to diffuse goiter and thyroid dysfunction. However, the effects of follicular lumen iodine, the main form of iodine reserve in the body, on thyroid-restricted genes in nodular goiter are poorly understood. In this study, correlations between follicular lumen iodine and the expressions of thyroid stimulating hormone receptor (TSHR), its transcription factors TTF-1, and PAX8 in nodular goiter were investigated. Patients. In this study, 30 resection specimens clinically histopathologically confirmed to have nodular goiter and 30 normal thyroid specimens from adjacent tissues of nodular goiter are used. Measurement. Western blot immunohistochemistry was performed to assay TSHR, TTF-1, and PAX8 in thyrocytes of nodular goiter as well as in extranodular normal thyroid tissues. Meanwhile, follicular lumen iodine of both nodular goiter and extranodular normal thyroid tissues was detected as well. Results. The TSHR, TTF-1, and PAX8 in nodular goiter were significantly higher than those in the controls. The iodine content in nodular goiter was significantly lower than those in control tissues. Conclusion. Upregulation of TSHR, TTF-1, and PAX8 is associated with low follicular lumen iodine content in nodular goiter.Entities:
Year: 2016 PMID: 27525008 PMCID: PMC4976194 DOI: 10.1155/2016/2492450
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Western blot assay for the expressions of TSHR, TTF-1, and PAX8 protein in nodular goiter and the control; β-actin is also detected as an internal control. The expressions of TSHR, TTF-1, and PAX8 in nodular goiter are significantly higher than those in the control. n = 10 (a, b). The iodine content (μg/mg) in nodular goiter was significantly lower than those in control tissues. n = 30 (c). P < 0.05; P < 0.01.
Figure 2Immunohistochemical analysis of the expressions and localization of TSHR, TTF-1, and PAX8 in nodular goiter and the control. The high expression of TSHR in nodular goiter is shown in (a), the moderate expression of TSHR in the controls is shown in (b); the upregulation of TTF-1 in nodular goiter is shown (c), and the moderate expression of TTF-1 in the controls is shown in (d). The high expression of PAX8 in nodular goiter is shown in (e), and the moderate expression of PAX8 in the controls is shown in (f).
Immunohistochemistry detecting TSHR in control and nodular goiter groups.
| Group | Staining result | |||||
|---|---|---|---|---|---|---|
| Cases ( | Negative | Positive | Strong positive | Positive rate (%) | Strong positive rate (%) | |
| Control | 30 | 0 | 30 | 8 | 100 | 26.7 |
| Nodular goiter | 30 | 0 | 30 | 26 | 100 | 86.7 |
P < 0.01.
Immunohistochemistry detecting TTF-1 in control and nodular goiter groups.
| Group | Staining result | |||||
|---|---|---|---|---|---|---|
| Cases ( | Negative | Positive | Strong positive | Positive rate (%) | Strong positive rate (%) | |
| Control | 30 | 0 | 30 | 12 | 100 | 40 |
| Nodular goiter | 30 | 0 | 30 | 24 | 100 | 80 |
P < 0.01.
Immunohistochemistry detecting PAX8 in control and nodular goiter groups.
| Group | Staining result | |||||
|---|---|---|---|---|---|---|
| Cases ( | Negative | Positive | Strong positive | Positive rate (%) | Strong positive rate (%) | |
| Control | 30 | 0 | 30 | 11 | 100 | 36.7 |
| Nodular goiter | 30 | 0 | 30 | 23 | 100 | 76.7 |
P < 0.01.